Importantly, we showed that Tofacitinib reduces the expression of PD-1, TIM-3, LAG-3, and CD28 induced by RA synovial fluid and TCR stimulation to levels similar to TCR-only stimulation. This evidence concerns the gene CD28 and rheumatoid arthritis.